These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28622841)

  • 1. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
    El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
    Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
    Wazir U; Mokbel K; Carmichael A; Mokbel K
    Cell Mol Biol Lett; 2017; 22():20. PubMed ID: 28878809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making.
    Ross E; Swallow J; Kerr A; Cunningham-Burley S
    Health Expect; 2019 Feb; 22(1):74-82. PubMed ID: 30387238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
    Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
    Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic subtypes in choosing adjuvant therapy for breast cancer.
    Zelnak AB; O'Regan RM
    Oncology (Williston Park); 2013 Mar; 27(3):204-10. PubMed ID: 23687790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors of early breast cancer].
    Almagro E; González CS; Espinosa E
    Med Clin (Barc); 2016 Feb; 146(4):167-71. PubMed ID: 25726309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
    Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
    Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
    Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
    Havard R; Henry NL
    Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
    [No Abstract]   [Full Text] [Related]  

  • 11. Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.
    Al-Allak A; Lewis PD; Bertelli G
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):1033-43. PubMed ID: 23030223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
    Lumachi F; Chiara GB; Foltran L; Basso SM
    Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
    Penault-Llorca F; Kwiatkowski F; Arnaud A; Levy C; Leheurteur M; Uwer L; Derbel O; Le Rol A; Jacquin JP; Jouannaud C; Quenel-Tueux N; Girre V; Foa C; Guardiola E; Lortholary A; Catala S; Guiu S; Valent A; Boinon D; Lemonnier J; Delaloge S
    Breast; 2020 Feb; 49():132-140. PubMed ID: 31790959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
    Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
    Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.
    Ribnikar D; Bedard PL
    Future Oncol; 2017 Dec; 13(30):2733-2736. PubMed ID: 29168649
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer genomics: real-time use.
    Bertucci F; Birnbaum D
    Lancet Oncol; 2007 Dec; 8(12):1045-1047. PubMed ID: 18054870
    [No Abstract]   [Full Text] [Related]  

  • 18. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
    Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
    Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
    Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
    Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.